NO20062763L - Pyrrolotriazinforbindelser som kinaseinhibitorer - Google Patents

Pyrrolotriazinforbindelser som kinaseinhibitorer

Info

Publication number
NO20062763L
NO20062763L NO20062763A NO20062763A NO20062763L NO 20062763 L NO20062763 L NO 20062763L NO 20062763 A NO20062763 A NO 20062763A NO 20062763 A NO20062763 A NO 20062763A NO 20062763 L NO20062763 L NO 20062763L
Authority
NO
Norway
Prior art keywords
compounds
formula
kinase inhibitors
useful
growth factor
Prior art date
Application number
NO20062763A
Other languages
English (en)
Norwegian (no)
Inventor
Gregory D Vite
Ashvinikumar Gavai
Wen-Ching Han
Ping Chen
Harold Mastalerz
John S Tokarski
Brian E Fink
Derek J Norris
Yufen Zhao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20062763L publication Critical patent/NO20062763L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20062763A 2003-12-29 2006-06-13 Pyrrolotriazinforbindelser som kinaseinhibitorer NO20062763L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53333503P 2003-12-29 2003-12-29
PCT/US2004/043169 WO2005066176A1 (en) 2003-12-29 2004-12-23 Pyrrolotriazine compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20062763L true NO20062763L (no) 2006-09-11

Family

ID=34748887

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062763A NO20062763L (no) 2003-12-29 2006-06-13 Pyrrolotriazinforbindelser som kinaseinhibitorer

Country Status (31)

Country Link
US (4) US7141571B2 (pt)
EP (2) EP2058314A1 (pt)
JP (1) JP4740878B2 (pt)
KR (1) KR100839716B1 (pt)
CN (1) CN1922182B (pt)
AR (1) AR047076A1 (pt)
AT (1) ATE443706T1 (pt)
AU (1) AU2004312413C1 (pt)
BR (1) BRPI0418231A (pt)
CA (1) CA2552107C (pt)
CL (1) CL2009001492A1 (pt)
CY (1) CY1109662T1 (pt)
DE (1) DE602004023324D1 (pt)
DK (1) DK1699797T3 (pt)
ES (1) ES2331842T3 (pt)
GE (1) GEP20105081B (pt)
HR (1) HRP20090601T1 (pt)
IL (1) IL176450A0 (pt)
MX (1) MXPA06007038A (pt)
MY (1) MY145634A (pt)
NO (1) NO20062763L (pt)
NZ (2) NZ573544A (pt)
PE (1) PE20050679A1 (pt)
PL (1) PL1699797T3 (pt)
PT (1) PT1699797E (pt)
RU (1) RU2373209C2 (pt)
SI (1) SI1699797T1 (pt)
TW (1) TWI332840B (pt)
UA (1) UA89038C2 (pt)
WO (1) WO2005066176A1 (pt)
ZA (1) ZA200605160B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
EP1497019B1 (en) * 2002-04-23 2015-05-20 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
US7358256B2 (en) 2005-03-28 2008-04-15 Bristol-Myers Squibb Company ATP competitive kinase inhibitors
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
US8338594B2 (en) * 2005-12-02 2012-12-25 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
US8063208B2 (en) * 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
US20100136137A1 (en) * 2006-11-01 2010-06-03 Bristol-Meyers Squibb Company Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound
KR101502634B1 (ko) 2007-02-08 2015-03-16 코덱시스, 인코포레이티드 케토 환원 효소 및 이의 용도
US20090076034A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched bms-690514
CA2704125A1 (en) * 2007-12-19 2009-07-09 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
JP2010209058A (ja) * 2008-09-29 2010-09-24 Sumitomo Chemical Co Ltd 1−置換−トランス−4−(置換アミノ)ピペリジン−3−オールの製造方法
EP2344504B1 (en) * 2008-10-08 2014-06-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
CA2750047A1 (en) 2009-01-21 2010-07-29 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
TW201107328A (en) * 2009-07-28 2011-03-01 Daiichi Sankyo Co Ltd Pyrrolo [2,3-d] pyrimidine derivatives
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基-雜芳基衍生物及其使用方法
KR101789129B1 (ko) 2010-06-30 2017-11-20 후지필름 가부시키가이샤 신규 니코틴아미드 유도체 또는 그 염
CN102153558B (zh) * 2011-02-23 2012-11-21 扬州永济医药新技术有限公司 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法
DE102011119127A1 (de) * 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
SMT202400142T1 (it) * 2014-01-13 2024-05-14 Aurigene Oncology Ltd Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
EP3143392B1 (en) * 2014-05-12 2023-02-22 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen metabolites by mass spectrometry
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
US12030897B2 (en) 2018-05-08 2024-07-09 Medshine Discovery Inc. Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof
EP4424312A3 (en) 2019-04-12 2025-01-08 Blueprint Medicines Corporation Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
WO2021088987A1 (zh) * 2019-11-08 2021-05-14 南京明德新药研发有限公司 作为选择性her2抑制剂的盐型、晶型及其应用
MX2023002233A (es) 2020-08-24 2023-03-15 Gilead Sciences Inc Compuestos fosfolipidos y usos de estos.
US20240132521A1 (en) * 2022-08-22 2024-04-25 Iambic Therapeutics, Inc. Compounds and methods for modulating her2
US20250345339A1 (en) * 2024-02-20 2025-11-13 Iambic Therapeutics, Inc. Doses and regimens of her2 inhibitors
CN121202763A (zh) * 2025-06-12 2025-12-26 成都道合尔医药技术有限公司 (3r,4r)-n-pg-4-氨基-3-甲基哌啶及其中间体的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283281B6 (cs) * 1992-09-25 1998-02-18 Eli Lilly And Company Způsob přípravy v poloze 5 substituovaných pyrrolo(2,3-d)pyrimidinů
CA2163399A1 (en) 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
TR199900389T2 (xx) 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CZ303660B6 (cs) * 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
KR100847605B1 (ko) 2000-11-17 2008-07-21 브리스톨-마이어스스퀴브컴파니 p38 키나제 관련 질병의 치료 방법 및 키나제 억제제로서유용한 피롤로트리아진 화합물
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
JP2005529890A (ja) * 2002-04-23 2005-10-06 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
EP1497019B1 (en) 2002-04-23 2015-05-20 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US6894066B2 (en) 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
WO2004013145A1 (en) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds

Also Published As

Publication number Publication date
US7141571B2 (en) 2006-11-28
CA2552107A1 (en) 2005-07-21
DK1699797T3 (da) 2010-01-04
GEP20105081B (en) 2010-09-27
HRP20090601T1 (hr) 2009-12-31
NZ548070A (en) 2009-02-28
CN1922182A (zh) 2007-02-28
US20050182058A1 (en) 2005-08-18
TW200526226A (en) 2005-08-16
MY145634A (en) 2012-03-15
PT1699797E (pt) 2009-12-29
ZA200605160B (en) 2007-12-27
US20090048244A1 (en) 2009-02-19
US20060264438A1 (en) 2006-11-23
HK1088332A1 (en) 2006-11-03
KR20060107828A (ko) 2006-10-16
NZ573544A (en) 2010-04-30
AU2004312413C1 (en) 2011-01-27
US7297695B2 (en) 2007-11-20
US20110039838A1 (en) 2011-02-17
CY1109662T1 (el) 2014-08-13
JP2007518721A (ja) 2007-07-12
CN1922182B (zh) 2010-08-18
EP2058314A1 (en) 2009-05-13
CL2009001492A1 (es) 2010-01-15
RU2006127396A (ru) 2008-02-10
BRPI0418231A (pt) 2007-04-27
ES2331842T3 (es) 2010-01-18
SI1699797T1 (sl) 2010-04-30
JP4740878B2 (ja) 2011-08-03
EP1699797B1 (en) 2009-09-23
EP1699797A1 (en) 2006-09-13
ATE443706T1 (de) 2009-10-15
MXPA06007038A (es) 2006-08-31
AU2004312413B2 (en) 2010-07-22
IL176450A0 (en) 2006-10-05
DE602004023324D1 (de) 2009-11-05
CA2552107C (en) 2011-10-18
PE20050679A1 (es) 2005-09-25
WO2005066176A1 (en) 2005-07-21
PL1699797T3 (pl) 2010-02-26
US7846931B2 (en) 2010-12-07
UA89038C2 (en) 2009-12-25
TWI332840B (en) 2010-11-11
AR047076A1 (es) 2006-01-04
KR100839716B1 (ko) 2008-06-19
RU2373209C2 (ru) 2009-11-20
AU2004312413A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
NO20052733L (no) C-6 modifiserte indazolylpyrrolotriaziner
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
NO20091708L (no) Nye kinase inhibitorer
MXPA05000715A (es) Inhibidores novedosos de cinasas.
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
NO20090580L (no) Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
YU84603A (sh) Novi inhibitori tirozin kinaze
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2004009542A3 (en) Process for preparing certain pyrrolotriazine compounds
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005065266A8 (en) Di-substituted pyrrolotriazine compounds
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
DE602005023732D1 (de) Pyrrolotriazinverbindungen
NO20063324L (no) 3-cyano-kinolinderivater med antiproliferativ aktivitet
ATE370147T1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
NO20072667L (no) Fremstillingsmetode
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application